$10.44
-0.1-0.95%
Last update: Oct 30, 7:59 PM
Puma Biotechnology Inc (PBYI) Stock Price, Quote, News & History
PBYINASDAQ
A Delaware jury ordered AstraZeneca to pay Pfizer $107.5 million, ruling that AstraZeneca's lung cancer drug Tagrisso infringed on Pfizer's patents related to...
You can purchase shares of Puma Biotechnology (NASDAQ:PBYI) through any online brokerage.
Other companies in Puma Biotechnology’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Puma Biotechnology has a consensus price target of $6.50.
The stock price for Puma Biotechnology (NASDAQ: PBYI) is $10.7191 last updated October 30, 2026 at 7:59 PM EDT.
There are no upcoming dividends for Puma Biotechnology.
Puma Biotechnology does not have any upcoming earnings scheduled.
There is no upcoming split for Puma Biotechnology.
Puma Biotechnology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for...
